K-TECH Solutions Company Limited (KMRK)

CTI BioPharma Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023
Cash & Equivalents	5.64	5.39	2.34
Cash & Short-Term Investments	5.64	5.39	2.34
Cash Growth	-	130.44%	-
Accounts Receivable	3.2	1.22	1.76
Other Receivables	0.03	0.03	0.1
Receivables	3.23	1.25	1.85
Prepaid Expenses	0.14	0.01	0.01
Other Current Assets	0	0	0
Total Current Assets	9.01	6.65	4.2
Property, Plant & Equipment	0.54	0.66	0.93
Long-Term Deferred Tax Assets	0.03	0.02	0
Total Assets	9.57	7.33	5.13
Accounts Payable	4.2	3.23	2.27
Accrued Expenses	0.3	0.09	0.09
Current Portion of Long-Term Debt	0.2	0.19	0.16
Current Portion of Leases	0.09	0.11	0.16
Current Income Taxes Payable	0.22	0.14	-
Current Unearned Revenue	0.44	0.52	0.67
Other Current Liabilities	0.15	0.15	0.04
Total Current Liabilities	5.6	4.43	3.39
Long-Term Debt	0.94	0.43	0.11
Long-Term Leases	0.15	0.19	0.28
Total Liabilities	6.69	5.05	3.78
Retained Earnings	2.87	2.28	1.35
Comprehensive Income & Other	0.02	0	-0
Shareholders' Equity	2.88	2.28	1.35
Total Liabilities & Equity	9.57	7.33	5.13
Total Debt	1.37	0.92	0.72
Net Cash (Debt)	4.26	4.47	1.61
Net Cash Growth	-	176.47%	-
Net Cash Per Share	0.22	0.23	0.08
Filing Date Shares Outstanding	19.5	19.5	19.5
Total Common Shares Outstanding	19.5	19.5	19.5
Working Capital	3.4	2.22	0.81
Book Value Per Share	0.15	0.12	0.07
Tangible Book Value	2.88	2.28	1.35
Tangible Book Value Per Share	0.15	0.12	0.07
Machinery	0.1	0.1	0.1
Leasehold Improvements	0.48	0.48	0.48

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q